Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of GSK Neisseria Gonorrhoeae GMMA (NgG) Vaccine in Healthy Adults
NCT05630859Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2022
- Primary completion
- May 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of NgG vaccine in gonorrhea (7 arms), sponsored by GSK. Primary endpoints: Number of Participants Reporting Any Solicited Administration Site Events, Number of Participants Reporting Any Solicited Systemic Events and 4 more. Started Nov 2022; status: completed.
02
Drugs
NgG vaccine
03
Conditions
gonorrhea
Beyond the preview
Go deeper on NCT05630859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630859.